Linking glucocorticoid action and hypoxia: a novel mechanism driving an adverse metabolic phenotype? by Hazlehurst, J

Non-alcoholic fatty liver disease in common endocrine disorders. by Hazlehurst, J, Tomlinson, J

Glucocorticoids and non-alcoholic fatty liver disease. by Woods, C, Hazlehurst, J, Tomlinson, J

Non-alcoholic fatty liver disease and diabetes. by Hazlehurst, J, Woods, C, Marjot, T, Cobbold, J, Tomlinson, J

Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospit... by Marjot, T, Sbardella, E, Moolla, A, Hazlehurst, J, Tan, G, Ainsworth, M, Cobbold, J, Tomlinson, J

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. by Armstrong, M, Hazlehurst, J, Hull, D, Guo, K, Borrows, S, Yu, J, Gough, S, Newsome, P, Tomlinson, J

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis by Armstrong, M, Hazlehurst, J, Hull, D, Guo, K, Borrows, S, Yu, J, Gough, S, Newsome, P, Tomlinson, J

A comparative quality assessment of evidence-based clinical guidelines in endocrinology. by Hazlehurst, J, Armstrong, M, Sherlock, M, Rowe, I, O'Reilly, M, Franklyn, J, Stewart, P, Tomlinson, J

Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo. by Hazlehurst, J, Gathercole, L, Nasiri, M, Armstrong, M, Borrows, S, Yu, J, Wagenmakers, A, Stewart, P, Tomlinson, J

Urinary Glucocorticoid Metabolite Excretion is Associated with Insulin Resistance Independent of BMI in Patients with Polycystic Ovary Syndrome by O'Reilly, M, Hodson, J, Hazlehurst, J, Lebbe, M, Hughes, B, Stewart, P, Tomlinson, J, Arlt, W

SFRP2 is associated with increased adiposity and VEGF expression. by Crowley, R, O'Reilly, M, Bujalska, I, Hassan-Smith, Z, Hazlehurst, J, Foucault, D, Stewart, P, Tomlinson, J

Genotype-phenotype correlation in Bardet-Biedl Syndrome by Forsythe, E, Sparks, K, Huda, M, Hazlehurst, J, Muajhid, S, Carroll, P, McGowan, B, Tomlinson, J, Mohammed, S, Beales, P

Subcutaneous adipose tissue insulin resistance and lipolysis in patients with nonalcoholic steatohepatitis by Armstrong, M, Hazlehurst, J, Hull, D, Borrows, S, Guo, K, Yu, J, Barton, D, Gaunt, P, Gough, S, Tomlinson, J, Newsome, P

Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes by Marjot, T, Green, CJ, Charlton, CA, Cornfield, T, Hazlehurst, J, Moolla, A, White, S, Francis, J, Neubauer, S, Cobbold, JFL, Hodson, L, Tomlinson, JW

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. by Armstrong, M, Hull, D, Guo, K, Barton, D, Hazlehurst, J, Gathercole, L, Nasiri, M, Yu, J, Gough, S, Newsome, P, Tomlinson, J

Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure by Lim, T, Hazlehurst, J, Oprescu, A, Armstrong, M, Abdullah, S, Davies, N, Flintham, R, Balfe, P, Mutimer, D, McKeating, J, Tomlinson, J

Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II r... by Armstrong, M, Hull, D, Guo, K, Barton, D, Hazlehurst, J, Nasiri, M, Gathercole, L, Yu, J, Gaunt, P, Gough, S, Tomlinson, J, Newsome, P

Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. by Armstrong, M, Hazlehurst, J, Parker, R, Koushiappi, E, Mann, J, Khan, S, Philips, A, Chandler, L, Johnson, J, Round, M, Haydon, G, Karamat, M, Newsome, P, Tomlinson, J

Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstrom syndrome. by Gathercole, L, Hazlehurst, J, Armstrong, M, Crowley, R, Boocock, S, O'Reilly, M, Round, M, Brown, R, Bolton, S, Cramb, R, Newsome, P, Semple, R, Paisey, R, Tomlinson, J, Geberhiwot, T

Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. by Hazlehurst, J, Oprescu, A, Nikolaou, N, Di Guida, R, Grinbergs, A, Davies, N, Flintham, R, Armstrong, M, Taylor, A, Hughes, B, Yu, J, Hodson, L, Dunn, W, Tomlinson, J